This Biotech Ramped 60% Higher Monday in Anticipation of Cellulite Trial Data

165
Soliton

Most of the time, small biotech companies see massive price swings on positive or negative clinical trials regarding a major drug their developing. However, sometimes investors are so eagerly anticipating a drug candidate that prices could swing merely on the expectations of future results.

That’s exactly what happened on Monday as Soliton (NASDAQ: SOLY), a small medical technology company, which surged when It announced that they would be releasing their 26-week patient data from its study.

Surging over 60 percent over the course of the day, Soliton was Monday’s biggest winner on the stock markets.

Specifically, Soliton’s flagship product is called the Soliton rapid Acoustic Pulse device, which is applied to the surface of someone’s skin as a non-invasive treatment option for cellulite.

Although the project is currently in a proof-of-concept stage, investors familiar with the company have kept a close eye out on this particular study, especially since there are already positive signs that it’s been a success.



“We were excited and encouraged by the initial patient results we saw when the trial treatments were completed,” said Chris Capelli, Soliton President, Chief Science Officer and co-founder.  “Those initial results suggested that Soliton has the potential for a new approach to treating cellulite.  Our excitement has continued to grow as we have tracked the patient responses to the treatment and we look forward to presenting what will be 26 weeks of data on July 15.  This data forms the foundation for the protocol development for our recently announced expanded pivotal Clinical Cellulite Trial to launch later this summer.”

The treatment is unique in comparison to other cellulite treatment options in that it doesn’t require anesthesia, causes no bruising, swelling, infection, or other complications. At the same time, trial participants said the treatment was completely painless, rating it as a “0” on a pain scale from 0-10 in 97 percent of the cases. At the same time, none of the patients experienced any post-treatment downtime.

Earlier this year, Soliton announced that the cellulite trial would involve 75 patients across four locations alongside some of the top physicians in this medical field. While the Soliton device hasn’t been reviewed or cleared by Federal regulatory bodies yet, positive results from the study would likely move the project on to that stage, with clinical trials and eventually approval from the FDA within a year or two.

Investors are also excited for Soliton’s new project specifically because of how large the potential market is. Around 90 percent of women have some form of cellulite, representing billions of dollars annually on treatment options in the U.S. alone.

Shares of Soliton spiked by 62 percent in anticipation of these trial results, getting close to breaking the $20 price point. Since February, Soliton’s stock price quadrupled from $4.62 to its current price point of $18.50.

Soliton Company Profile

Soliton Inc a medical technology company focused on developing and commercializing products utilizing its proprietary designed acoustic shockwave technology platform referred to as RAP. Its business model anticipates generating revenue from the sale of RAP console to dermatologists, plastic surgeons, and other physician offices, as well as medi-spas. – Warrior Trading News

NO COMMENTS

LEAVE A REPLY